Mar 4, 2022
#HD14-516P#DEUTSCH(Khross electronics co.크로스전자에서) https://www.instagram.com/p/Caq49lJJFrp/?utm_medium=tumblr
Loading...
seen from Germany
seen from United States
seen from Canada
seen from Canada
seen from Australia
seen from Brazil
seen from United States
seen from United Kingdom
seen from Australia
seen from Canada
seen from United States
seen from Malaysia
seen from Canada
seen from Australia
seen from Germany
seen from Canada
seen from United Kingdom
seen from Canada
seen from Russia
seen from Germany
#HD14-516P#DEUTSCH(Khross electronics co.크로스전자에서) https://www.instagram.com/p/Caq49lJJFrp/?utm_medium=tumblr
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Diskon 51% PF Antena Dalam - Indoor Digital Model HD14
Diskon 51% PF Antena Dalam – Indoor Digital Model HD14
View On WordPress
Does quality control of IF-RT for patients with early stage Hodgkin`s lymphoma make sense?
In order to improve the quality of radiotherapy (RT) treatment for study patients with early stage Hodgkin`s lymphoma, the German Hodgkin Study Group (GHSG) set up a RT reference center within the Department of Radiation Oncology at the University of Cologne. The evaluation of disease spread and individual staging within the trials HD 10/11 and HD13/14 is based on a central radiation oncologic review of a patient`s entire diagnostic imaging and clinical findings.
The purpose of the given analysis was the re-evaluation of the effectiveness of such a quality assurance (QA) program within the trials HD13/14 and its impact on further treatment. Moreover, the results of the two study generations (HD10/11 vs. HD13/14) were compared: A considerable proportion of involved anatomic sites were recorded incorrectly by the participating study centers. Compared to the findings in HD 10/11, no improvement of the correctness of the documented disease involvement could be seen.
Thus, a QA program and meticulous evaluation of all imaging information in close collaboration between radiation oncologist and diagnostic radiologist is mandatory.
http://www.ncbi.nlm.nih.gov/pubmed/22692351
By CMac
Final results of the HD14 trial
Von Tresckow and colleagues recently reported the final results of the HD14 trial in early unfavorable hodgkin disease patients. In this prospective randomized (1:1) trial it was compared whether a combination of 2x BEACOPP-escalated plus 2x ABVD (arm B) was superior to the old standard 4x ABVD (arm A), both regimens followed by 30 Gy involved-field RT. Altogether 1655 patients were recruited whereas 1528 were eligible for evaluation. Acute toxicity was significantly higher in arm B with 87.1% acute toxicity (G3+4) compared to 50.7% in arm A. Four pts died in arm B because of acute toxicities whereas no one died in arm A, but no significant difference could be derived concerning treatment-related mortality or secondary malignancies. 5-y freedom-from-treatment failure rate was siginificantly better in arm B (94.8% vs. 87.7%, p < 0,001), a significant difference was also observed in PFS but not in OS (due to effective salvage therapies). These results underscore that 2 + 2 plus 30 Gy IFRT is the new GHSG standard for patients with early unfavorable HD age 60 years or younger. Link: http://www.ncbi.nlm.nih.gov/pubmed/22271480 Further reading on early unfavorable ("intermediate") stages: HD17 (ongoing): http://www.ncbi.nlm.nih.gov/pubmed/18956517 (principles of IN RT) HD11: http://www.ncbi.nlm.nih.gov/pubmed/20713848 HD8: http://www.ncbi.nlm.nih.gov/pubmed/12913100 HD5: http://www.ncbi.nlm.nih.gov/pubmed/11786577 HD1-3: http://www.ncbi.nlm.nih.gov/pubmed/2438613 by MNiy